Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More than three decades since its initial description in 1993, Brugada syndrome remains engulfed in controversy. This review aims to shed light on the main challenges surrounding the diagnostic pathway and criteria, risk stratification of asymptomatic patients, pharmacological and interventional risk modification strategies as well as our current pathophysiological understanding of the disease.

More information Original publication

DOI

10.15420/ecr.2019.12.2

Type

Journal article

Publication Date

2019-12-01T00:00:00+00:00

Volume

14

Pages

169 - 174

Total pages

5

Keywords

Brugada syndrome, ICD, quinidine, radiofrequency ablation